Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- polatuzumab vedotin
- repotrectinib
Interactions between your drugs
polatuzumab vedotin repotrectinib
Applies to: polatuzumab vedotin, repotrectinib
Repotrectinib may decrease the blood levels and effects of polatuzumab vedotin. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
repotrectinib food
Applies to: repotrectinib
Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib. This may increase the risk and/or severity of side effects such as dizziness, tiredness, muscle pain, nausea, change in your sense of taste, feeling numbness or tingling in your arms or legs, constipation, trouble with balance, shortness of breath, problems with thinking such as forgetfulness or confusion and hallucinations, as well as more serious side effects such severe or life-threatening inflammation of the lungs and liver injury. Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.